References in periodicals archive ?
The Company's drug pipeline consists of one product in Phase II/III clinical development for an orphan indication in a neuromuscular disease -- as well as an advanced preclinical pipeline, including calpain inhibitors for Duchenne Muscular Dystrophy, MC4-receptor antagonists for cancer cachexia and Dipeptidyl-peptidase 4 inhibitors for Type 2 diabetes.
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Full browser ?